Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Degradation of Aiolos and Ikaros Followed By Downregulation of c-Myc and then IRF4 Leads to Programmed Cell Death in Myeloma Cells Sensitive to IMiDs ® Immunomodulatory Compounds

Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Patrick R Hagner, PhD, Anita K. Gandhi, PhD, Maria Wang, PhD, Michael D Amatangelo, PhD, Ling Lu, BS, Huisheng Wang, MS, Mike Breider, DVM, PhD DACVP, Yan Ren, MS, Antonia Lopez-Girona, PhD, Anjan Thakurta, PhD, Anke Klippel, PhD, Rajesh Chopra, MD PhD

Blood (2014) 124 (21): 4700.

https://doi.org/10.1182/blood.V124.21.4700.4700

Published: 2014

Journal Articles

CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide

Jemma Blocksidge, Mark Glenn, Anita K. Gandhi, PhD, Anke Klippel, PhD, Michael Pourdehnad, MD, Rajesh Chopra, MD PhD, Nagesh Kalakonda

Blood (2014) 124 (21): 4682.

https://doi.org/10.1182/blood.V124.21.4682.4682

Published: 2014

Journal Articles

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Patrick Hagner, PhD, Maria Wang, PhD, Suzana Couto, PhD, Mike Breider, DVM, PhD DACVP, Celia Fontanillo, PhD, Matthew Trotter, PhD, Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Heather K Raymon, PhD, Rama Krishna Narla, PhD, Leo Barnes, PhD, Michelle Waldman, MS, Tom Daniel, MD, Anke Klippel, PhD, Michael Pourdehnad, MD, Anjan Thakurta, PhD, Rajesh Chopra, MD, PhD, Anita K. Gandhi, PhD

Blood (2014) 124 (21): 3035.

https://doi.org/10.1182/blood.V124.21.3035.3035

Published: 2014

Journal Articles

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Vincent Ribrag, MD, Silvia Damien, MD, Mecide Gharibo, MD, Mercede Gironella, MD, Armando Santoro, MD, Drew W Rasco, MD, William Edenfield, MD, Xin Wei, PhD, Angela James, PhD, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Jorge F. DiMartino, MD PhD, Michael Pourdehnad, MD, Anne-Marie Stoppa, MD

Blood (2014) 124 (21): 3500.

https://doi.org/10.1182/blood.V124.21.3500.3500

Published: 2014

Journal Articles

Lenalidomide Promotes Degradation of Casein Kinase 1a (CK1a) through Cereblon: Implications for the Efficacy of Lenalidomide in MDS and AML

Paul Hollenbach, Ling Lu, BS, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Kyle J MacBeth, PhD

Blood (2014) 124 (21): 3606.

https://doi.org/10.1182/blood.V124.21.3606.3606

Published: 2014

Journal Articles

IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance

Courtney G. Havens, PhD, Chad Bjorklund, PhD, Jian Kang, BS, Maria Ortiz, PhD, Celia Fontanillo, PhD, Michael Amatangelo, PhD, Ling Lu, BS, Paola E. Neri, MD PhD, Antonia Lopez-Girona, PhD, Nizar J. Bahlis, MD, Anjan Thakurta, PhD, Mathew Trotter, MD, Anita K. Gandhi, PhD, Anke Klippel, PhD, Rajesh Chopra, MD PhD

Blood (2014) 124 (21): 3432.

https://doi.org/10.1182/blood.V124.21.3432.3432

Published: 2014

Journal Articles

Dual-Color CRBN/CD138 Immunohistochemistry Assay for Measuring Cereblon Protein in Samples from Patients with Multiple Myeloma

Yan Ren, MS, Maria Wang, PhD, Suzanne Couta, DVM, PhD DACVP, Donna Hansel, MD, Karen Miller, BS, Antonia Lopez-Girona, PhD, Chad C Bjorklund, PhD, Anita K. Gandhi, PhD, Anjan Thakurta, PhD, Rajesh Chopra, MD PhD, Michael Breider, DVM, PhD DACVP

Blood (2014) 124 (21): 6021.

https://doi.org/10.1182/blood.V124.21.6021.6021

Published: 2014

Journal Articles

Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β-Thalassemia

Michael Dussiot, Thiago Maciel, PhD, Aurelie Fricot, Joel Veiga, Etienne Paubelle, Emmanuel Payen, Yves Beuzard, MD, Jean-Antoine Ribeil, MD, PhD, Jean-Benoît Arlet, MD, Genevieve Courtois, PhD, Tom O Daniel, MD, PhD, Rajesh Chopra, MD, PhD, Victoria Sung, Ph.D., Olivier Hermine, MD, PhD, Ivan Cruz Moura, PhD

Blood (2012) 120 (21): 247.

https://doi.org/10.1182/blood.V120.21.247.247

Published: 2012

Journal Articles

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

Anita K Gandhi, PhD, Derek Mendy, BS, Anastasia Parton, BA, Lei Wu, MS, ECFMG, Jolanta Kosek, BA, Ling-Hua Zhang, PhD, Lori Capone, BS, Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 2963.

https://doi.org/10.1182/blood.V120.21.2963.2963

Published: 2012

Journal Articles

Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias

Peter H Schafer, PhD, Emily Rychak, PhD, Derek Mendy, BS, Anastasia Parton, BA, Lori Capone, BS, Antonia Lopez-Girona, PhD, Jilly F Evans, PhD, Tom O Daniel, MD, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 1055.

https://doi.org/10.1182/blood.V120.21.1055.1055

Published: 2012

Journal Articles

Inhibition of B Cell Differentiation to the Plasmablast and Plasma Cell Lineage by CC-220, a Potent Modulator of the CRBN E3 Ubiquitin Ligase Complex

Peter H Schafer, PhD, Lori Capone, BS, Lei Wu, MS, ECFMG, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 3279.

https://doi.org/10.1182/blood.V120.21.3279.3279

Published: 2012

Journal Articles

Exposures and Erythropoietic Responses to Sotatercept (ACE-011) in Healthy Volunteers and Cancer Patients: Implications for Mechanism of Action

Nianhang Chen, Ph D, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Simon Zhou, PhD, Victoria Sung, PhD, Maria Palmisano, MD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 3454.

https://doi.org/10.1182/blood.V120.21.3454.3454

Published: 2012

Journal Articles

Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression

Ling-Hua Zhang, PhD, Jolanta Kosek, BA, Maria Wang, Ph.D., Carla Heise, PhD, Peter H Schafer, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 3287.

https://doi.org/10.1182/blood.V120.21.3287.3287

Published: 2012

Journal Articles

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Soraya Carrancio, PhD, Jennifer A Markovics, PhD, Piu Wong, PhD, Jim Leisten, Matthew C Groza, Heather K Raymon, Carla Heise, PhD, Rajesh Chopra, MD, PhD, Tom O Daniel, MD, PhD, Victoria Sung, PhD

Blood (2012) 120 (21): 372.

https://doi.org/10.1182/blood.V120.21.372.372

Published: 2012

Journal Articles

Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138 + multiple Myeloma Cells

Anita K Gandhi, PhD, Herve Avet-Loiseau, MD, Michelle Waldman, MS, Anjan Thakurta, PhD, Sharon L Aukerman, PhD, Gengxin Chen, PhD, Derek Mendy, BS, Emily Rychak, PhD, Karen Miller, Svetlana Gaidarova, MS, Michael Gonzales, Brian Cathers, PhD, Peter H Schafer, PhD, Tom O Daniel, MD, PhD, Antonia Lopez-Girona, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 4043.

https://doi.org/10.1182/blood.V120.21.4043.4043

Published: 2012

NARROW

Degradation of Aiolos and Ikaros Followed By Downregulation of c-Myc and then IRF4 Leads to Programmed Cell Death in Myeloma Cells Sensitive to IMiDs ® Immunomodulatory Compounds

CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Lenalidomide Promotes Degradation of Casein Kinase 1a (CK1a) through Cereblon: Implications for the Efficacy of Lenalidomide in MDS and AML

IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance

Dual-Color CRBN/CD138 Immunohistochemistry Assay for Measuring Cereblon Protein in Samples from Patients with Multiple Myeloma

Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β-Thalassemia

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias

Inhibition of B Cell Differentiation to the Plasmablast and Plasma Cell Lineage by CC-220, a Potent Modulator of the CRBN E3 Ubiquitin Ligase Complex

Exposures and Erythropoietic Responses to Sotatercept (ACE-011) in Healthy Volunteers and Cancer Patients: Implications for Mechanism of Action

Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138 + multiple Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only